论文部分内容阅读
目的探究与分析呼吸机相关性肺炎临床治疗的效果及安全性。方法 46例呼吸机相关性肺炎,采取随机数字表法分为对照组与试验组,每组23例。对照组给予头孢吡肟治疗,试验组给予头孢哌酮/舒巴坦治疗,观察与对比两组患者的治疗效果及细菌清除率。结果试验组与对照组相比治疗总有效率及病原菌总清除率明显提升,差异具有统计学意义(P<0.05)。结论头孢哌酮/舒巴坦治疗呼吸机相关性肺炎的临床疗效显著,同时要求临床工作者能够对致病菌的分布情况给予判断并制定有效的防治措施,以降低呼吸机相关性肺炎的发生率。
Objective To explore and analyze the clinical effect and safety of ventilator-associated pneumonia. Methods 46 cases of ventilator-associated pneumonia were randomly divided into control group and trial group, with 23 cases in each group. The control group was given cefepime, and the experimental group was treated with cefoperazone / sulbactam. The therapeutic effect and bacterial clearance of the two groups were observed and compared. Results Compared with the control group, the total effective rate of treatment and the total clearance rate of pathogenic bacteria in experimental group and control group increased significantly (P <0.05). Conclusions Cefoperazone / sulbactam is effective in the treatment of ventilator-associated pneumonia, meanwhile clinicians are required to be able to judge the distribution of pathogens and to develop effective prevention and treatment measures to reduce the occurrence of ventilator-associated pneumonia rate.